McKesson may take over fellow distributor Celesio; Baxter nabs FDA approval for IV supplement;

@FiercePharma: Trending this a.m. online: Forget drug-sales forecasts, study finds. They're usually wrong. Who does it best? Article | Follow @FiercePharma

@CarlyHFierce: From FierceVaccines: GlaxoSmithKline targeting a 2015 launch for its malaria vaccine. Report | Follow @CarlyHFierce

> German drug distributor Celesio's shares leapt after media reported a potential takeover by U.S.-based McKesson ($MCK). Report

> Baxter Healthcare ($BAX) won FDA approval for Clinolipid, an intravenous nutritional supplement, after a priority review to help alleviate a drug shortage. Report

> PhRMA says it will set up a Middle East and Africa regional office at DuBiotech, a free zone in Dubai, UAE. Report

> A U.S. District judge delayed the planned transfer of hundreds of lawsuits over injuries allegedly caused by Merck's ($MRK) bone drug Fosamax to allow more time for settlement talks. Report

> China's CONBA Pharma said its profits so far this year are up about 70%. Report

> Doctors continue to overprescribe antibiotics, especially to patients with a sore throat or bronchitis, which usually can't be treated with bacteria-fighting drugs. Report

> Texas officials refused to return execution drugs to a compounding pharmacy that wants them back. Report

Medical Device News

@FierceMedDev: New special report: Med tech's hottest takeover targets for the rest of 2013. Feature | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics is expanding through a Peabody, MA acquisition (My old professional stomping grounds.) News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Alnylam posts positive PhI for RNAi cholesterol drug. Story from FierceDrugDelivery | Follow @MichaelGFierce

> ProTip's artificial larynx successfully implanted in male patient. More

> Tandem seeks $100M IPO amid burgeoning market. Story

> Biomet buying Lanx with eye on spinal implants. News

Biotech News

@FierceBiotech: Special Report: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Want to buy a million-square-foot monument to Merck's past glory? More | Follow @JohnCFierce

@DamianFierce: The FDA outlines its shutdown activities--nothing that hasn't been reported, but a handy document no less. More | Follow @DamianFierce

> Post-restructuring, Pfizer R&D focused on its top blockbuster prospects. More

> J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail. News

> Versartis nabs $20M to take growth hormone to PhIII. Story

> Bayer spotlights its late-stage pipeline contenders in cancer, cardio. Article

Pharma Manufacturing News

@EricPFierce: Projecting $140M annual operating losses, Boehringer says Ben Venue plant not worth keeping open. Story | Follow @EricPFierce

> Aesica fined $161,000 for worker injury. Report

> Sartorius picking up TAP Biosystems in $45M deal. Story

> Recipharm, Fujifilm expand their biologics capabilities. Article

> Ranbaxy may look to buy FDA-approved plant in India. Item

Biotech Research News

@EmilyMFierce: There's a Major Foodborne Illness Outbreak and the Government's Shut Down. More from Wired | Follow @EmilyMFierce

> Three U.S.-based scientists jointly win Nobel Prize for cell transport discoveries. Article

> $6.25M grant establishes leukemia research initiative. Item

> Yale team investigates promising new class of antidepressants. Story

> Chemical in red wine kills cancer cells even after it's metabolized. More

And Finally... A Swedish study found no evidence to support theories of a viral cause for breast cancer and a type of brain tumor. Release

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.